EMA Recommends Granting a Marketing Authorisation for Lutetium (177Lu) Vipivotide Tetraxetan
It is indicated for the treatment of adult patients with progressive PSMA-positive mCRPC
Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
It is indicated for the treatment of adult patients with progressive PSMA-positive mCRPC
CheckMate 227 Part 1 efficacy and safety data with a minimum follow-up of 5 years
Findings from the phase II expansion of the IMCgp100-102 study
Findings from a post hoc analysis of KEYNOTE-048 after an approximately 4-year follow-up
Efficacy was evaluated in SIOPEL 6 and COG ACCL0431 studies
Findings from a pre-specified second interim analysis of overall survival and updates in other OlympiA study endpoints
Findings from a pooled data analysis of the SAFIR02-BREAST and SAFIR-PI3K studies
Findings from the NordICC Study Group trial
Sorafenib Accord is a generic of Nexavar, which has been authorised in the EU since 2006
Efficacy was evaluated in TAS-120-101 study in patients with previously treated, unresectable, locally advanced, or metastatic intrahepatic cholangiocarcinoma harbouring a FGFR2 gene fusion or other rearrangement
Findings from a phase I, dose-escalation study of a second-generation CAR T-cells in patients with relapsed or refractory multiple myeloma
Findings from the CheckMate 915 study primary endpoints of recurrence-free survival in the all randomised population and in patients with tumour PD-L1 expression < 1%
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.